Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV Clinical Trial
Official title:
A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC)
This is a Phase I, open label multicentre study of selumetinib administered orally in
combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC.
The study has been designed to allow an investigation of the optimal dose of selumetinib in
combination with various standard first line double-platinum chemotherapy regimens. Initial
assessment will be based on tolerability of selumetinib in combination with one or more
selected regimens that are considered to be tolerated also being assessed for preliminary
evidence of activity.
This study is a dose finding and optional cohort expansion; In addition all patients will be
assessed for anti-cancer efficacy of the combination of selumetinib and chemotherapy.
A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination with First Line Chemotherapy Regimens in Patients with Non-Small Cell Lung Cancer (NSCLC) ;